Nature Technology Corporation

Other

Ophidian Pharmaceuticals, Inc.

Promega Corporation

Medtronic, Inc.

Equi-Tech Labs, Inc.

Allergan, Inc.

Deutsches Krebsforschungszentrum

Quick Connectors, Inc.

Restoragen, Inc.

Aldevron, LLC

Allergan Botox Limited

Absolute Comfort, Inc.

James Arthur Williams

John A Kink

Aaron E Carnes

Sean B Carroll

Peng Luan

Yuannan Xia

Clague P Hodgson

Christopher M Clemens

Scott Harley

Tod D Emerson

Lisa Marie Byrne

Bruce S Thalley

Richard Harbottle

Charles S G Pugh

Robert K Halbert

Colton Jones

Matthias Bozza

The present invention relates to a polynucleotide comprising at least one promoter and an S/MAR element, wherein the S/MAR element is located downstream of the promoter in the 3' UTR of the transcription unit and wherein the S/MAR element is flanked by a 5′ splice donor site and a 3′ splice acceptor site; the present invention further relates to a composition comprising the polynucleotide, and to the polynucleotide for use in medicine and for use in treating genetic disease.

Non-integrating DNA vectors for the genetic modification of cells

A eukaryotic replicative pUC-free minicircle expression vector is provided. The eukaryotic replicative pUC-free minicircle expression vector includes a pUC-free eukaryotic region sequence encoding a transgene of interest and comprising 5′ and 3′ ends and a ii) pUC-free spacer region of less than 500 basepairs in length linking the 5′ and 3′ ends of the eukaryotic region sequences and comprising a bacterial R6K replication origin having at least 95% sequence identity to SEQ ID NO: 11 and SEQ ID NO: 12 and a RNA selectable marker, the RNA selectable marker being an RNA-IN regulating RNA-OUT functional variant having at least 95% sequence identity to SEQ ID NO: 20 or SEQ ID NO: 22.

Replicative minicircle vectors with improved expression

The present invention relates to the production and use of covalently closed circular (ccc) recombinant plasmids, and more particularly to vector modifications that improve expression of said DNA molecules in the target organism.

DNA plasmids with improved expression

The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules.

A eukaryotic replicative pUC-free minicircle expression vector is provided. The eukaryotic replicative pUC-free minicircle expression vector includes a pUC-free eukaryotic region sequence encoding a transgene of interest and comprising 5' and 3&#x2032; ends and ii) a pUC-free spacer region of less than 500 basepairs in length linking the 5&#x2032; and 3&#x2032; ends of the eukaryotic region sequences and comprising a bacterial R6K replication origin having at least 95% sequence identity to SEQ ID NO: 11 or SEQ ID NO: 12 and a RNA selectable marker, the RNA selectable marker being an RNA-IN regulating RNA-OUT functional variant having at least 95% sequence identity to SEQ ID NO:20 or SEQ ID NO:22.

The present disclosure provides a dis-connectable wellhead hanger arrangement permitting a pig tail set of a electrical conductors to be inserted within the wellhead hanger arrangement which seals against the wellhead hanger upon separation of an electrical power cable. If the power cable separates from the production tubing for any reason, the compressively fit plugs disconnect the power cable from the pathway leaving the electrical mandrel sealed within the wellhead hanger, thereby sealing the wellhead hanger from loss of fluid after separation.

Disconnectable pressure-preserving electrical connector and method of installation

The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of these DNA molecules.

The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.

Methods of DNA constructs for high yield production of polypeptides

Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.

Vectors and methods for genetic immunization

General methods and strains of bacteria are described that dramatically simplify and streamline plasmid DNA production. In one preferred embodiment, endolysin mediated plasmid extraction combined with flocculation mediated removal of cell debris and host nucleic acids achieves increased yield and purity with simplified downstream purification and reduced waste streams, thus reducing production costs.

[object Object]

The present invention relates to recombinant DNA molecules such as plasmids, non-viral vectors, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules in cell lines and organisms.

Growing community of inventors

Lincoln, NE, United States of America

James Arthur Williams